Clinical Trials Logo

Clinical Trial Summary

The purpose of this trial is to investigate the safety and efficacy of GEN1046 as monotherapy and in combination with pembrolizumab in patients with non-small cell lung cancer who have failed previous standard of care.


Clinical Trial Description

This trial is a randomized, open-label trial evaluating the safety and efficacy of GEN1046 as monotherapy and in combination therapy with pembrolizumab. The trial consists of two parts; a safety phase and an extension phase. The extension phase will be initiated once the safety phase is completed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05117242
Study type Interventional
Source Genmab
Contact Genmab A/S Trial Information
Phone +45 70202728
Email [email protected]
Status Recruiting
Phase Phase 2
Start date October 27, 2021
Completion date November 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03168464 - Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) Phase 1/Phase 2
Completed NCT04470440 - Thyroid Dysfunction and Nivolumab Reponse in NSCLC
Active, not recruiting NCT03304093 - Immunotherapy by Nivolumab for HIV+ Patients Phase 2
Active, not recruiting NCT04069936 - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC Phase 2
Active, not recruiting NCT03307785 - Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 Phase 1
Recruiting NCT03533127 - A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer Phase 3
Recruiting NCT04187768 - Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer
Not yet recruiting NCT04951583 - Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma Phase 2
Active, not recruiting NCT03133546 - Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) Phase 2
Active, not recruiting NCT03845270 - Her2-positive Lung Cancer Treated With Dedicated Drug Phase 2
Recruiting NCT03774732 - PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer Phase 3
Recruiting NCT04621188 - Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) Phase 2
Active, not recruiting NCT03235765 - Cancer Panel From Blood of Lung Cancer Patients
Not yet recruiting NCT03732482 - Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases Phase 2/Phase 3
Active, not recruiting NCT02978404 - Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases Phase 2
Recruiting NCT03977194 - Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy Phase 3
Completed NCT01658813 - 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer Phase 2
Recruiting NCT04233021 - Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation Phase 2
Completed NCT03123783 - CD40 Agonistic Antibody APX005M in Combination With Nivolumab Phase 1/Phase 2
Recruiting NCT03715985 - Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac) Phase 1/Phase 2